Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2015

Open Access 01-12-2015 | Research

Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali

Authors: Hamma Maiga, Abdoulaye A Djimde, Abdoul H Beavogui, Ousmane Toure, Mamadou Tekete, Cheick Papa O Sangare, Antoine Dara, Zoumana I Traore, Oumar B Traore, Souleymane Dama, Christelle N’Dong, Hamidou Niangaly, Nouhoum Diallo, Demba Dembele, Issaka Sagara, Ogobara K Doumbo

Published in: Malaria Journal | Issue 1/2015

Login to get access

Abstract

Background

Plasmodium falciparum resistance to artemisinin has been reported in South-East Asia. Long half-life drugs are increasingly being used for malaria prevention. The potential spread of parasite resistance to these regimens is real and makes regular efficacy surveillance a priority.

Methods

From August to December 2004 and July to December 2005, a randomized open label trial of sulphadoxine-pyrimethamine (SP) + artesunate (AS) versus SP + amodiaquine (AQ), and SP alone, was conducted in two villages of Mali. PCR was used to distinguish new infections from recrudescent P. falciparum infections. Patients were followed for 28 days to assess treatment efficacy.

Results

Overall 912 children aged between six to 59 months, with uncomplicated P. falciparum malaria were recruited. Baseline characteristics were similar in the three treatment arms. Crude ACPRs were 94.9%; 98.6% and 93.5% for SP + AS; SP + AQ and SP alone arms respectively (SP + AS versus SP + AQ, p = 0.01; SP + AS versus SP, p = 0.5; SP + AQ versus SP, p = 0.001). After PCR adjustment, cACPRs were 99%; 100% and 97.2% for SP + AS; SP + AQ and SP alone arms, respectively (SP + AS versus SP + AQ, p = 0.25; SP + AS versus SP, p = 0.12; SP + AQ versus SP, p = 0.007).

Conclusion

Sulphadoxine-pyrimethamine + amodiaquine therapy was as efficacious as sulphadoxine-pyrimethamine + artesunate, but more efficacious than sulphadoxine-pyrimethamine alone in the treatment of uncomplicated P. falciparum malaria in Mali.
Literature
1.
Sangho H, Diawara A, Diallo M, Sow S, Sango HA, Sacko M, et al. Assessment of chloroquine resistance two years after stopping chemoprophylaxis in 0 to 9-year-old children living in a malaria-endemic village of Mali](in French). Med Trop (Mars). 2004;64:506–10.
2.
De Radigues X, Diallo KI, Diallo M, Ngwakum PA, Maiga H, Djimde A, et al. Efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Koumantou, Mali. Trans R Soc Trop Med Hyg. 2006;100:1013–8.CrossRefPubMed
3.
Djimde AA, Barger B, Kone A, Beavogui AH, Tekete M, Fofana B, et al. A molecular map of chloroquine resistance in Mali. FEMS Immunol Med Microbiol. 2010;58:113–8.CrossRefPubMedCentralPubMed
4.
WHO and UNICEF. World malaria report 2005. In: WHO/HTM/MAL /2005.1102. Geneva: World Health Organization; 2005.
5.
Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg. 2008;78:455–61.PubMed
6.
Sagara I, Dicko A, Djimde A, Guindo O, Kone M, Tolo Y, et al. A randomized trial of Artesunate-sulfamethoxypyrazine pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg. 2006;75:630–6.PubMed
7.
WHO. Resistance to artemisinin derivatives along the Thai-Cambodian border. Wkly Epidemiology Rec. 2007;82:360.
8.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.CrossRefPubMedCentralPubMed
9.
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRefPubMedCentralPubMed
10.
Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, et al.. Independent emergence of Plasmodium falciparum artemisinin resistance mutations in Southeast Asia. J Infect Dis. 2014. [Epub ahead of print]
11.
WHO Geneva 2001. who.int/hq/2001/WHO_CDS_RBM_2001.35
12.
Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis. 2005;192:1823–9.CrossRefPubMedCentralPubMed
13.
Kayentao K, Mungai M, Parise M, Kodio M, Keita AS, Coulibaly D, et al. Assessing malaria burden during pregnancy in Mali. Acta Trop. 2007;102:106–12.CrossRefPubMed
14.
Tekete M, Djimde AA, Beavogui AH, Maiga H, Sagara I, Fofana B, et al. Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. Malar J. 2009;8:34.CrossRefPubMedCentralPubMed
15.
Plowe CV, Djimde A, Wellems TE, Kouriba B, Doumbo OK. Community pyrimethamine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am J Trop Med Hyg. 1996;55:467–71.PubMed
16.
Sogoba N, Vounatsou P, Bagayoko MM, Doumbia S, Dolo G, Gosoniu L, et al. Spatial distribution of the chromosomal forms of Anopheles gambiae in Mali. Malar J. 2008;7:205.CrossRefPubMedCentralPubMed
17.
Diallo DA, Doumbo OK, Plowe CV, Wellems TE, Emanuel EJ, Hurst SA. Community permission for medical research in developing countries. Clin Infect Dis. 2005;41:255–9.CrossRefPubMed
18.
WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated malaria. Geneva: World Health Organization; 2003.
19.
Lyke KE, Diallo DA, Dicko A, Kone A, Coulibaly D, Guindo A, et al. Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. Am J Trop Med Hyg. 2003;69:253–9.PubMed
20.
Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257–63.CrossRefPubMed
21.
Tanabe K, Mackey M, Goman M, Scaife J. Allelic dimorphic in a surface antigen gene of P. falciparum. J Mol Biol. 1987;195:273–87.CrossRefPubMed
22.
Ranford-Cartwright LC, Taylor J, Umasunthar T, Taylor LH, Babiker HA, Lell B, et al. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg. 1997;91:719–24.CrossRefPubMed
23.
Kayentao K, Maiga H, Newman R, McMorrow LM, Hoppe A, Yattara O, et al. Artemisinin-based combinations versus amodiaquine plus sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje. Mali Malar J. 2009;8:5.CrossRef
24.
Rwagacondo CE, Niyitegeka F, Sarushi J, Karema C, Mugsha V, Dujardin JC, et al. Efficacy of amodiaquine alone and combined with sulphadoxine-pyrimethamine and of sulphadoxine-pyrimethamine combined with artesunate. Am J Trop Med Hyg. 2003;68:743–7.PubMed
25.
Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine Clinical implications. Clin Pharmacokinet. 1996;30:263–99.CrossRefPubMed
26.
EANMAT. The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health. 2003;13:860–7.
27.
Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S. Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malar J. 2007;6:146.CrossRefPubMedCentralPubMed
28.
Rulisa S, Gatarayiha JP, Kabarisa T, Ndayisaba G. Comparison of different artemisinin-based combinations for the treatment of Plasmodium falciparum malaria in children in Kigali, Rwanda, an area of resistance to sulfadoxine-pyrimethamine: artesunate plus sulfadoxine/pyrimethamine versus artesunate plus sulfamethoxypyrazine/pyrimethamine. Am J Trop Med Hyg. 2007;13:612–6.
29.
Djallé D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J. 2014;13:9.CrossRefPubMedCentralPubMed
30.
Mbacham WF, Evehe MS, Netongo PM, Ateh IA, Mimche PN, Ajua A, et al. Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy. Malar J. 2010;9:34.CrossRefPubMedCentralPubMed
31.
Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, Soulama I, et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomized, double blind, and placebo controlled trial. PLoS Med. 2011;8:e1000408.CrossRefPubMedCentralPubMed
32.
Dicko A, Barry A, Dicko M, Diallo AI, Tembine I, Dicko Y, et al. Malaria morbidity in children in the year after they had received intermittent preventive treatment of malaria in Mali: a randomized control trial. PLoS ONE. 2011;6:e23390.CrossRefPubMedCentralPubMed
33.
Metadata
Title
Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali
Authors
Hamma Maiga
Abdoulaye A Djimde
Abdoul H Beavogui
Ousmane Toure
Mamadou Tekete
Cheick Papa O Sangare
Antoine Dara
Zoumana I Traore
Oumar B Traore
Souleymane Dama
Christelle N’Dong
Hamidou Niangaly
Nouhoum Diallo
Demba Dembele
Issaka Sagara
Ogobara K Doumbo
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2015
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-015-0557-y

Other articles of this Issue 1/2015

Malaria Journal 1/2015 Go to the issue

Research

Long-lasting insecticidal net source, ownership and use in the context of universal coverage: a household survey in eastern Rwanda

Research

Genetic diversity of Plasmodium vivax in clinical isolates from Bangladesh

Research

Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea

Research

Seasonality of Plasmodium falciparum transmission: a systematic review

Research

Distinct genetic difference between the Duffy binding protein (PkDBPαII) of Plasmodium knowlesi clinical isolates from North Borneo and Peninsular Malaysia

Research

Identification of important interacting proteins (IIPs) in Plasmodium falciparum using large-scale interaction network analysis and in-silico knock-out studies
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits